Mana Medical raises £475K for wearable-powered rheumatic monitoring

What's the deal? Mana MedicalDealroom has a profile for this one. Try Dealroom →, a UK digital health company serving people with rheumatic and autoimmune conditions, has raised £475,000 in a round backed by the FundMyPitchDealroom has a profile for this one. Try Dealroom → investor network. It will use the capital to speed product development and expand clinical deployment.

What's the endgame? Mana's platform connects to a patient's existing wearable, learns their movement patterns, and combines activity data with symptom, medication, and journal inputs to flag hidden triggers behind flare-ups. Patients get real-time pacing nudges and daily guidance; clinicians get a live view of their caseload.

Why now? Rheumatic care is largely reactive. Patients are reviewed in episodic snapshots, often months apart, and clinicians rely on patient recall in between — so by the time a flare presents in clinic, the window to intervene early has usually passed.

Mana aims to close that gap by letting clinicians adjust medication remotely rather than waiting for the next appointment.

What they said: "Rheumatic disease affects millions of people and has seen far too little innovation, so it resonated quickly with the right investors in our network," said Steven Mooney, founder and chief executive officer of FundMyPitch.

The signal: The round reflects investor appetite for wearable-driven monitoring in an underserved corner of digital health. FundMyPitch connects early-stage SEIS and EIS companies with more than 3,700 investors, placing Mana among a growing set of startups betting that continuous data can shift chronic care from reactive to preventive.

Read more: ukbaa.org.uk

Image credit: Generated with Gemini